Sirtris Pharmaceuticals Presents at American Chemical Society April 7
April 01 2008 - 8:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced that
it will be presenting at the American Chemical Society annual
meeting in New Orleans on Monday, April 7 at 7:00 pm EDT. Jean
Bemis, Sirtris Associate Director of Chemistry, will present an
abstract on the identification of novel small molecule activators
of SIRT1, the founding member of the sirtuin family of enzymes
associated with diseases of aging. Using high throughput mass
spectrometry, Sirtris has identified new chemical entity (NCE)
activators of SIRT1 that are chemically distinct from, and up to
1000 times more potent in in-vitro studies than resveratrol, the
compound shown to reduce glucose and improve insulin sensitivity in
preclinical studies. Sirtris� NCEs have been shown to lower glucose
and improve insulin sensitivity in predictive pre-clinical models
of Type 2 Diabetes. SIRT1 activators have the potential to be a
frontline therapy for Type 2 Diabetes. Sirtris plans to have one of
its NCEs in a Phase 1 human clinical safety trial in the first half
of 2008. About Sirtris Pharmaceuticals Sirtris Pharmaceuticals is a
biopharmaceutical company focused on discovering and developing
proprietary, orally available, small molecule drugs with the
potential to treat diseases associated with aging, including
metabolic diseases such as Type 2 Diabetes. Our drug candidates are
designed to mimic certain beneficial health effects of calorie
restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
the Company believes control the aging process. Sirtris
Pharmaceuticals is engaged in human clinical trials for Type 2
Diabetes, and is planning similar trials in cancer, another
age-related disease. Sirtris is also engaged in a human clinical
trial for MELAS, a mitochondrial disorder. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, the potential therapeutic effects
of SIRT1 activators including NCEs for diseases of aging, such as
Type 2 Diabetes; the success of SIRT1 activators as therapies for
diseases, such as Type 2 Diabetes; the progress and results of
preclinical and clinical studies of SIRT1 activators, such as
SRT501 and Sirtris� NCEs; and the potential of sirtuin modulators
to receive regulatory approval. These forward-looking statements
about future expectations, plans and prospects of Sirtris
Pharmaceuticals involve significant risks, uncertainties and
assumptions, including risks related to the lack of results that
would provide a basis for predicting whether any of the Company's
product candidates will be safe or effective, or receive regulatory
approval, the possibility that results of pre-clinical studies are
not necessarily predictive of clinical trial results, the Company's
potential inability to initiate and complete pre-clinical studies
and clinical trials for its product candidates, the fact that none
of the Company's product candidates has received regulatory
approvals, the potential inability of the Company to gain market
acceptance of the Company's product candidates, and those other
risks factors that can be found in the Company's filings with the
Securities and Exchange Commission. Actual results may differ
materially from those Sirtris Pharmaceuticals contemplated by these
forward-looking statements. Sirtris Pharmaceuticals does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024